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Abstract
Background: Commercial MLPA kits (MRC-Holland) are available for detecting imbalance at the
subtelomere regions of chromosomes; each kit consists of one probe for each subtelomere.
Methods: For validation of the kits, 208 patients were tested, of which 128 were known to be
abnormal, corresponding to 8528 genomic regions overall. Validation samples included those with
trisomy 13, 18 and 21, microscopically visible terminal deletions and duplications, sex chromosome
abnormalities and submicroscopic abnormalities identified by multiprobe FISH. A robust and
sensitive analysis system was developed to allow accurate interpretation of single probe results,
which is essential as breakpoints may occur between MLPA probes.
Results: The validation results showed that MLPA is a highly efficient technique for medium-
throughput screening for subtelomere imbalance, with 95% confidence intervals for positive and
negative predictive accuracies of  0.951-0.996 and 0.9996-1 respectively. A diagnostic testing
strategy was established for subtelomere MLPA and any subsequent follow-up tests that may be
required. The efficacy of this approach was demonstrated during 15 months of diagnostic testing
when 455 patients were tested and 27 (5.9%) abnormal cases were detected.
Conclusion:  The development of a robust, medium-throughput analysis system for the
interpretation of results from subtelomere assays will be of benefit to other Centres wishing to
implement such an MLPA-based service.
Background
Genomic imbalance at the subtelomeres of chromosomes
has been found in individuals with idiopathic mental
retardation, dysmorphic features and/or congenital
abnormalities. The reported incidence is dependent on
referral group: Joyce et al [1] found no imbalance in 200
patients with idiopathic mental retardation but without
dysmorphism; whilst Rio et al [2] report that 10.7% of
patients with severe idiopathic mental retardation were
found to have subtelomere imbalance. Data collated from
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20 studies found that of 2,500 patients with mental retar-
dation, 4.8% were found to have deletion or duplication
of subtelomeric sequences [3] and the investigation of an
impressive cohort (11,688 cases) by Ravnan et al [4],
found 2.5% had clinically significant subtelomere imbal-
ance, with most referred for developmental delay with or
without dysmorphic features. This prevalence indicates
that testing would be justified in appropriate referral
groups. However, until recently the diagnostic potential of
subtelomere testing has been limited by the technology
available, with the majority of diagnostic centres employ-
ing a laborious and expensive multiprobe FISH approach
[5].
The development and availability of multiplex ligation-
dependent probe amplification (MLPA) for the accurate
assessment of copy number at multiple loci has provided
a new approach for subtelomere testing. This elegant tech-
nique can assess 48 loci in a single reaction and lends
itself to cost-effective medium-throughput testing. An
impressive number of MLPA studies has been published
since the technique was first described in 2002 [6]. The
majority of these studies have used commercial MLPA
assays (MRC-Holland) to detect deletions and duplica-
tions of exons causing single gene disorders [7-9]. How-
ever, most cases of submicroscopic subtelomere
imbalance involve duplication or deletion of a single sub-
telomere and therefore in current, commercial assays, a
single MLPA probe. This is in contrast to MLPA testing for
single gene disorders, where contiguous exon aberrations
generally involve multiple MLPA probes. Furthermore,
exon testing-MLPA assays incorporate designated control
probes from outside of the tested region; commercial sub-
telomere assays do not contain any such designated con-
trol probes and any probe may show a change in copy
number. Thus the strategy used to analyse MLPA data for
the detection of subtelomere imbalance needs to be
shown to produce robust single probe results in the
absence of control probes. Several analytical models have
been proposed [10-12] and five studies [10-14] using
these analysis models are summarised in Table 1. The
abnormality detection rate ranged from 1.8% to 5.9% and
the detection rate for inherited abnormalities or polymor-
phisms ranged from 0% to 6.2% (it should be noted that
some of the probesets used in these studies are now
known to contain probes that detect polymorphic loci).
Further studies have demonstrated higher detection rates,
especially if more stringent clinical criteria are used to
select the patient cohort [10,15,16].
Although these studies demonstrated that MLPA was able
to detect submicroscopic imbalance, few known abnor-
mal loci have been tested by MLPA. Thus the sensitivity of
MLPA and incidence of false negative results is unknown.
This is of particular importance if diagnostic laboratories
wish to replace multiprobe FISH with MLPA. The false
negative rate will depend on the robustness of the MLPA
technique itself and the analysis method used, either of
which could result in miscalled negative results, and the
experimental approach, which depending on the number
of probes analysed may fail to identify a region of imbal-
ance. In this paper, we describe the validation of MLPA for
diagnostic testing in a service laboratory, including the
testing of a large number of known abnormal loci, and the
analysis protocol developed based on the validation data.
We also review the results of the first 15 months of our
diagnostic MLPA subtelomere testing service.
Methods
DNA extraction
DNA was extracted from blood samples received in EDTA
using the Chemagic Automated DNA Separation System
(Chemagen, Germany) following the manufacturer's
instructions. DNA was also extracted in a minority of cases
using the Puregene DNA extraction kit (Gentra Systems,
USA) following the manufacturer's instructions or a salt-
chloroform extraction method [17]. All DNA was quanti-
fied by fluorometry (Picogreen, Invitrogen, UK) or spec-
trophotometry (Nanodrop, USA) and checked for
degradation on an agarose gel. Degraded DNA was not
used for MLPA analysis.
MLPA
Four MLPA subtelomeric probesets (MRC-Holland, The
Netherlands) were used: P019 and P020 (which together
test all the subtelomeres), P036 versions A & B (which
each test all the subtelomeres) and P069 (which tests all
the subtelomeres except those of the acrocentric chromo-
Table 1: A summary of published results using MLPA to identify subtelomere imbalance.
Report Samples Abnormala Inherited/Polymorphismb Phenotype
Rooms (2004) 75 4 (5.3%) - Mental retardation
Koolen (2004) 210 8 (3.8%) 6 (2.9%) Mental retardation
Northrop (2005) 51 3 (5.9%) - Mental retardation, congenital abnormalities
Kirchhoff (2005) 258 13 (5.0%) 16 (6.2%) Mental retardation, dysmorphic features
Rooms (2006) 275 5 (1.8%) 7 (2.5%) Mental retardation
a Reported as likely to be clinically significant.
b P019, P020 and/or P036A assays used, which contain some probes now known to detect polymorphic loci.BMC Medical Genetics 2007, 8:9 http://www.biomedcentral.com/1471-2350/8/9
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some short arms); P069 was released by MRC-Holland as
a replacement for P019 and P020 during the course of the
validation study. All patient samples were tested with a
combination of P019+P020, P036A/B and P069, so that
at least two loci were tested at each subtelomeric region.
All probes for any subtelomeric region were analysed
independently of each other. Any MLPA results for the
'short arms' of the acrocentric chromosomes were not
considered significant as these probes hybridise to the
long arm, near the centromere.
The MLPA kits were used to test 250 ng of DNA according
to the manufacturer's protocol, with the following excep-
tions: (i) the PCR reaction was in a final volume of 25 µl;
(ii) 26 PCR cycles were performed. Five normal male con-
trol samples were included for each MLPA assay, along
with up to 88 patient DNA samples and one negative con-
trol.
A 3 µl aliquot of PCR product was mixed with 0.3 µl
Genescan 500 LIZ size standard (Applied Biosystems, UK)
and 15 µl HiDi formamide (Applied Biosystems, UK)
before being size-separated by capillary electrophoresis
on a 3100 genetic analyser (Applied Biosystems, UK).
Genescan and Genotyper software (Applied Biosystems,
UK) were used for fragment analysis, sizing and labelling
of product peaks.
MLPA data analysis
The peak height data was imported into a spreadsheet-
based automated analysis system, which has been exten-
sively validated. The system contained a series of quality
checks to ensure that analysis was only performed when
suitable data had been collected. These checks included
ensuring that all peaks were present and labelled correctly,
and that all peak heights were between 50–6000 arbitrary
fluorescent units.
Dosage quotients were chosen to form the basis of the
analysis where:
As dosage quotients are a relative measure, normalisation
(transforming data points to have the same mean) was
not necessary to take into account the differences in peak
heights between samples.
Although peak heights have been used to calculate dosage
quotients in this study, they can be successfully substi-
tuted with peak area measurements, as demonstrated by
an evaluation of  >100 MLPA tests (data not shown).
However, using peak heights has practical advantages as
occasionally all peaks in a sample become very broad and
Genescan analysis software may quantify peak area inac-
curately. Peak height is not affected by this phenomenon
and therefore, to maximise efficiency, it is preferable at
our Centre to use peak heights for calculating dosage quo-
tients.
A series of dosage quotients was generated for each peak
by using individual neighbouring peaks as reference
peaks, rather than generating a single dosage quotient for
each peak by using an average of reference peaks. This
avoids the situation whereby an abnormal peak may sig-
nificantly alter the result of neighbouring peaks.
The control "test : reference" ratios were calculated for
each of five controls and the mean of these ratios formed
the denominator for the dosage quotient formula. Averag-
ing the control ratios was necessary at this point to allow
for inter-sample variability (including the differing
degrees of tail-off observed between traces, discussed
below). Coefficients of variation for the control "test : ref-
erence" ratios were calculated and each individual MLPA
probe was considered valid only if there was less than
10% variation between the five control samples.
The normal range was defined as the square root of the
expected theoretical ratios for deletions and duplications,
i.e.  √(0.5) – √(1.5), to avoid using subjective values.
Importantly, this produces a normal range that is asym-
metric around a 1:1 ratio, which reflects the biology. Each
dosage quotient for a peak was called "deleted", "normal"
or "duplicated" depending on where it fell in relation to
the normal range. In addition, dosage quotients that were
<0.5 or >1.5 were highlighted, as artefactual peaks occa-
sionally occurred and were typically much larger or
smaller than expected and hence gave very high or low
dosage quotients.
The modal (majority) call over the series of dosage quo-
tients for each test peak gave the final result. An example
of the dosage quotients generated for each sample is
shown in table 2. To minimise the effects of differential
tail-off mentioned above, a series of ten dosage quotients
was generated for each probe by only using the ten neigh-
bouring peaks as individual reference peaks. Reducing the
amount of template DNA was not found to reduce the
tail-off or differences in tail-off. Figure 1 illustrates a pair
of traces, showing differences in tail-off between patient
and control samples. Figure 2 illustrates the result of "glo-
bal" normalisation (where each peak is normalised
against all other peaks in that sample), whereas Figure 3
shows the same patient sample analysed by the method
described in this paper. If more than 5 of the dosage quo-
tients indicated a duplication or deletion, the result for the
MLPA probe was classed as abnormal; abnormal results
are however generally represented by 9 or 10 abnormal
Dosage Quotient  
height of patient test peak
height of patie
=
n nt reference peak
mean height of control test peak
height of   control reference peak ()BMC Medical Genetics 2007, 8:9 http://www.biomedcentral.com/1471-2350/8/9
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dosage quotients. Finally, the analysis system produced a
summary table listing each MLPA probe for each patient
and whether it indicated a deletion, duplication or nor-
mal copy number. For any sample exhibiting abnormal
probe results, the test was repeated with the same assay to
show consistency and any inconsistent results were
rejected. Our spreadsheets are available on request.
Fluorescence in situ hybridisation
All subtelomeric abnormalities identified by MLPA were
subsequently tested using single, chromosome-specific
subtelomeric probes from Abbott-Vysis (ToTelVysion;
UK), Cytocell (Aquarius; UK) or MP Biomedicals (QBio-
gene; CA, USA). Multisubtelomere FISH was carried out as
previously described [18].
Sequencing
DNA was sequenced using the BigDye Terminator
sequencing kit (Applied Biosystems, UK) following the
manufacturer's instructions. The sequencing products
were analysed on a 3100 genetic analyser (Applied Biosys-
tems, UK).
Results
Validation Study
124 patients, previously diagnosed with chromosome
abnormalities were used in the validation study. A further
84 patients, referred for subtelomere screening during the
course of this study, were also included. Therefore in total,
208 patients were tested, corresponding to 8528 genomic
regions overall. Overall, 128 patients carried known
abnormalities, corresponding to 184 abnormal regions
and 415 tested abnormal loci. Validation cases included
those with trisomy 13, 18 and 21, microscopically visible
terminal deletions and duplications, sex chromosome
abnormalities and submicroscopic abnormalities identi-
fied by multiprobe FISH. MLPA probes for all subtelom-
eric regions were validated for detecting normal copy
number. Abnormal copy number detection was validated
at the following subtelomeric loci: del 1p, 2q, 3p, 4p, 5p,
7p, 7q, 8p, 10p, 10q, 11p, 11q, 13q, 14q, 17q, 18q, 22q,
Xp, Xq and dup 2q, 4p, 4q, 6p, 6q, 8p, 8q, 11p, 11q, 12p,
13p, 13q, 16q, 18p, 18q, 19q, 21p, 21q, 22p, Xp, Xq. All
data collected during the validation study were analysed
using the analysis method described above.
All known abnormal subtelomere regions were correctly
identified by MLPA: false negative rate = 0; negative pre-
dictive accuracy = 1 (95% CI = 0.9996–1). In three cases
with known abnormalities, the abnormality was only
detected by one of the two MLPA probes, with the other
probe hybridising to adjacent sequence of normal copy
number: deletion of 10p subtelomere detected by P036A
but not P019; deletion of Xp subtelomere detected by
P036A but not P019; duplication of 16q subtelomere
detected by P020 but not P036A. In all three cases, the
more proximal probe detected normal copy number, fur-
ther defining the breakpoint region.
One patient that had previously been diagnosed with
monosomy 2q37 by G-banded chromosome analysis
showed normal copy number for this region by MLPA.
Further studies using FISH confirmed the MLPA result,
and showed that the patient carried a balanced transloca-
tion between the long arm of chromosome 2 and the
short arm of chromosome 5.
For one patient that was referred for subtelomere screen-
ing during the course of the validation study, a single
MLPA probe (11p; P036A) indicated a deletion while the
Table 2: A section of the dosage quotient table generated for an abnormal sample.
6p 7p 8p 9p 10p 11p 12p 13p 14p 15p 16p
0.99 0.99 0.97 0.95 1.06 0.49 1.03 1.03 1.05 0.99 2.00
1.03 0.99 0.94 1.03 0.97 0.51 1.05 1.02 1.02 2.00 0.98
1.03 0.97 1.02 0.95 1.01 0.52 1.05 1.00 2.04 0.99 1.01
1.00 1.04 0.94 0.99 1.03 0.52 1.02 1.99 1.00 1.01 0.98
1.08 0.96 0.98 1.00 1.03 0.50 2.03 0.98 1.03 0.99 1.00
1.04 1.02 0.99 0.97 1.99 0.49 1.02 0.97 1.01 1.00 1.04
1.06 1.01 0.97 1.94 0.98 0.50 1.00 0.99 1.02 1.02 0.99
1.05 0.99 1.92 0.95 1.00 0.49 1.01 0.99 1.06 0.98 0.99
1.02 1.97 0.95 0.98 0.97 0.50 1.02 1.03 1.01 0.99 1.00
2.04 0.97 0.97 0.95 1.00 0.50 1.05 0.98 1.01 1.00 0.97
6p 7p 8p 9p 10p 11p 12p 13p 14p 15p 16p
NNNNN DEL NNNNN
The top and penultimate rows show the MLPA probe; each probe's 10 corresponding dosage quotients (generated from 10 flanking peaks) are 
shown in the column below. Abnormal ratios are highlighted in bold. The bottom row shows the result for each probe, where N signifies copy 
number of 2 and DEL signifies copy number of 1.BMC Medical Genetics 2007, 8:9 http://www.biomedcentral.com/1471-2350/8/9
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corresponding FISH test showed normal copy number. As
other samples were available, seven members of this fam-
ily were tested by MLPA. Interestingly, four affected family
members across three generations exhibited the same
deletion profile in the mucin 2 gene, whereas the three
unaffected family members showed a normal profile.
However, sequencing across the ligation site showed a
sequence change, 2bp downstream from the ligation site
(NM_002457.1:13593C>T) in all the "deleted" family
members. The altered DNA sequence did not cause a
change in the amino acid (isoleucine) and therefore the
segregation of this sequence change with the phenotype is
most likely to be coincidental in this family.
Another patient with a single MLPA probe deletion result
(4q; P069) was also sequenced. This patient showed three
base changes at the ligation site (NM_004477.2:133G>C,
134A>G, 135C>G). The MLPA ligation site for this probe
corresponds to 5'-UTR of the FSHD region gene 1 (FRG1);
further studies are required to determine whether these
changes could alter the expression of the gene.
In addition, three other patients that had been referred for
subtelomeric imbalance screening and that had been
diagnosed as normal using FISH, were found by MLPA
testing to carry abnormalities. In one of these cases, a sin-
gle MLPA probe indicated a duplication (Xp; P019), while
Analysis of the normal sample shown in Figure 1 using a global normalisation method (sample compared to 5 controls; normal  range 0.8 to 1.2) Figure 2
Analysis of the normal sample shown in Figure 1 using a global normalisation method (sample compared to 5 controls; normal 
range 0.8 to 1.2). A number of 'abnormal' results are generated.
MLPA (P036B) traces for a normal test sample (upper) and normal control (lower) showing differential tail-off Figure 1
MLPA (P036B) traces for a normal test sample (upper) and normal control (lower) showing differential tail-off.BMC Medical Genetics 2007, 8:9 http://www.biomedcentral.com/1471-2350/8/9
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another more distal MLPA probe in the same region indi-
cated normal copy number. The same probe indicated a
duplication in the patient's mother who also had the same
phenotype. We are waiting for samples from other family
members to investigate this finding further. Parental sam-
ples have also been requested for the two other cases to
help assess clinical significance; one interstitial duplica-
tion (12p; P020) which requires confirmation and one
terminal duplication (Xp; P036A & P069).
In these five cases, the MLPA either gave or could be giving
a false positive result in terms of dosage. Therefore the
minimum positive predictive accuracy for MLPA dosage =
0.974 (95% CI = 0.951 – 0.996). However by using MLPA
as part of an overall testing strategy that includes other
techniques such as sequencing and FISH, false positive
results can be avoided.
In summary, 184 known abnormal regions were identi-
fied by at least one of two MLPA probes. There were three
novel abnormal findings, which require further follow-up
testing to ascertain clinical significance. One patient was
found to be balanced although previously diagnosed for
monosomy 2qter. Therefore the validation study provided
additional information for four patients, while no known
abnormalities went undetected.
MLPA diagnostic service
Between January 2005 and May 2006, 463 patients
referred for subtelomeric imbalance screening were tested
using MLPA. Due to the higher throughput of MLPA com-
pared to multiprobe FISH, de Vries criteria [19] were not
applied, but instead all clinical referrals from our region
that requested subtelomere testing were screened. MLPA
was carried out using the P036B and P069 kits; the probe
loci in these two kits are different at each subtelomere.
Eight samples (1.7%) were not analysed as the DNA was
degraded; these were all retrospective requests and the
DNA had been extracted up to 10 years previously.
Out of the 455 patients tested, MLPA detected abnormal
copy number in 27 patients (5.9%), summarised in Tables
3 and 4. One of these (case 8) consisted of both a dupli-
cation (22q; 1 probe) and a deletion (9q; 2 probes),
which had not been detected by G-banded chromosome
analysis. FISH analysis has confirmed the deletion and we
are waiting for parental samples to aid assessing clinical
significance. The abnormal results therefore comprised 16
single and 12 double MLPA probe results. Three of the sin-
gle probe results were subsequently confirmed by another
technique, either FISH (case 21) or by testing other family
members (cases 20, 22). Sequence change at the ligation
site was detected in a further patient (case 15, see below)
and the remaining 12 unconfirmed single probe results
are currently undergoing further studies.
There were 13 cases with deletion profiles, three of which
were shown to be interstitial (cases 4, 13, 14); duplica-
tions made up 15 cases, six of which were shown to be
interstitial (cases 5, 20, 22, 23, 24, 26).
Further family members were tested for 13 of the 28
abnormal results: six of these (cases 1, 2, 3, 23, 26, 27)
were found to be de novo abnormalities, although cases
23, 26 and 27 were single probe results and need to be
Analysis of the normal sample shown in Figure 1 using the method described in this paper (sample compared to 5 controls;  normal range -5 to +5) Figure 3
Analysis of the normal sample shown in Figure 1 using the method described in this paper (sample compared to 5 controls; 
normal range -5 to +5). All results are normal.BMC Medical Genetics 2007, 8:9 http://www.biomedcentral.com/1471-2350/8/9
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confirmed; seven have been shown to be inherited. Of
these seven, the abnormality detected by MLPA had been
inherited from unaffected parents in two patients (cases 6
and 20). In a further three cases (5, 9 and 22), the same
abnormality was detected in affected family members. In
the remaining two cases (7 and 12), it remains unclear
whether the abnormality was segregating with phenotype.
Seven of the 16 single MLPA probe results indicated dele-
tions, four of which were detected by the 4q probe of the
P069 assay. One (case 21; 9p, P069) was confirmed by
FISH analysis. The other six cases were sequenced. Five
showed normal sequence (cases 13, 14, 16, 17 and 18).
One (case 15; 4q, P069) showed three heterozygous
sequence changes in the FRG1 gene
(NM_004477.2:133G>C, 134A>G, 135C>G). Interest-
ingly this was the same sequence change as that detected
in one of the patients in the validation study (see above).
Discussion
Previous publications [11,12,14] on the use of MLPA to
detect subtelomere imbalance recommended the use of
two different probes to identify abnormal subtelomeric
regions; both MLPA probes needed to demonstrate con-
cordance for an abnormal result to be called. However,
imbalance identified by only a single probe may be a true
positive result, as although some MLPA probes are only 4
bp apart (4q subtelomere), they can be as much as 1.2 Mb
apart (13q subtelomere) and have a median separation of
~40 Kb. Furthermore, regions of imbalance may stretch
away from the second locus tested when the breakpoint
lies between the two MLPA probes. Use of only concord-
ant two-probe results will therefore inevitably result in
some false negative results, as illustrated by three cases in
our validation study and three cases from our diagnostic
service. We therefore developed an analysis strategy that
generates reliable single probe results, an important devel-
Table 3: Summary of cases with two subtelomere MLPA probes indicating abnormal copy number.
Case MLPA result FISH studiesa Inheritance studies Clinical features
1 del 1pter - De novo, parents unaffected Developmental delay, mild dysmorphism
2 dup 1pter dup 1pter De novo, parents unaffected Severe developmental delay, congenital heart defect
3 del 2qter del 2qter De novo, parents unaffected Developmental delay, dysmorphism, IUGR
4 del 3pter Normal, distal - Developmental delay, severe learning difficulties, 
spastic quadriplegia, epilepsy
5 dup 3pter Normal, distal Inherited from affected parent Congenital heart defect, short stature, clinodactyly
6 dup 5qter - Inherited from unaffected parent Queried Rubinstein-Taybi syndrome
7 del 6qter - Inherited from parent (unknown phenotype) Severe developmental delay, microcephaly, no 
speech, seizures
8 del 9qter del 9qter - Developmental delay, microcephaly, speech 
difficulties, seizures
9 dup 15qter - Inherited from parent (unknown phenotype), 
also present in another affected family member
Developmental delay, tall stature, macrocephaly, 
single kidney
10 dup 16qter - - Developmental delay, cleft palate, hearing loss
11 del 17pter - - Severe developmental delay, microcephaly, no 
speech, significant learning difficulties, mild 
dysmorphism, short stature, bilateral optic atrophy
12 dup 19qter Normal, proximal Sibling (phenotype unknown) carries same 
duplication, further inheritance studies to 
follow
Faltered growth, short stature, microcephaly
a Result of FISH test and position of FISH probe relative to MLPA probes. No result indicates that no informative FISH probe or sample was 
available.BMC Medical Genetics 2007, 8:9 http://www.biomedcentral.com/1471-2350/8/9
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Table 4: Summary of cases with only one subtelomere MLPA probe indicating abnormal copy number.
Case MLPA resulta FISH studiesb Sequencing/qPCR Inheritance studies Clinical features
13 del 1pter
(P036B, proximal)
- No sequence changes - Developmental delay, dysmorphism
14 del 1pter
(P036B, proximal)
- No sequence changes - Severe developmental delay, dysmorphism
15 del 4qter
(P069, distal)
- Three base changes 
next to ligation site
- Severe developmental delay, microcephaly, 
finger contractures
16 del 4qter
(P069, distal)
- No sequence changes - Developmental delay, optic nerve 
hypoplasia
17 del 4qter
(P069, distal)
- No sequence changesc - Developmental delay, dysmorphism, 
arthrogryposis
18 del 4qter
(P069, distal)
- No sequence changesc --
19 dup 6qter
(P069, distal)
- - - Cleft palate, micrognathia
20 dup 8qter
(P036B, proximal)
- - Inherited from 
unaffected parent
Short stature, cardiac lesion, epicanthic 
folds
21 del 9pter
(P069, distal)
del 9pter - To follow Learning difficulties, microcephaly, 
heterochromatic irises, patches of 
hypopigmented hair, happy disposition
22 dup 9pter
(P069, distal)
Normal, distal - Present in affected 
sibling, further studies 
to follow
Developmental delay, mild dysmorphism, 
speech delay, prominent teeth
23 dup 9qter
(P069, distal)
Normal, distal - De novo, parents 
unaffected
Moderate learning difficulties, ventral-spetal 
defect, shaking, umbilical hernia
24 dup 13qter
(P069, distal)
Normal, distal - - Cleft palate, unilateral micropthalmia, 
coloboma
25 dup 15qter
(P069, distal)
Normal, proximal - - Congenital heart disease, cleft palate, short 
stature, ptosis
26 dup 22qter
(P069, proximal)
- - De novo, parents 
unaffected
Developmental delay, autoimmune liver 
disease
8 dup 22qter
(P036B, distal)
Normal, proximal - - Developmental delay, microcephaly, speech 
difficulties, seizures
27 dup 22qter
(P036B, distal)
Normal, proximal - De novo, parents 
unaffected
Developmental delay, hypospadias
a MLPA result, probeset and position of abnormal MLPA probe relative to normal MLPA probe.
b Result of FISH test and position of FISH probe relative to abnormal MLPA probe. No result indicates that no informative FISH probe or sample 
was available.
c Homozygous/hemizygous single base change detected 24 bp from ligation site.BMC Medical Genetics 2007, 8:9 http://www.biomedcentral.com/1471-2350/8/9
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opment for the introduction of MLPA into our clinical
diagnostic service.
Our analysis model was developed to minimise the effects
of differential tail-off, to remove bias caused by neigh-
bouring abnormal loci, and to have defined parameters
for calling deletions and duplications. A number of anal-
ysis approaches were investigated with these aims in
mind, in addition to avoiding false negative single probe
results due to technical or analytical artefacts, and mini-
mising analogous false positive results. Analysing MLPA
data involves comparing a test peak to a reference peak to
detect abnormal copy number. One method, initially pro-
posed by MRC Holland and used by Northrop et al [11]
and Koolen et al [10], normalised each peak against an
average of all peaks for that sample (global normalisa-
tion), and then generated a dosage ratio by comparison to
normalised control data. However, this method does not
account for the observed peak tail-off, where larger MLPA
products exhibit reduced peak heights compared to
smaller products, and in particular the variation in tail-off
between samples (both test samples and controls; see Fig-
ure 1) that appears to be unpredictable.
In the course of this study, extensive peak tail-off was
observed in a minority of samples, and in these cases, glo-
bal normalisation caused dosage ratios to vary away from
1 (Figure 2). When global normalisation was used in a
previous study [10], ~18% of MLPA traces were failed. To
minimise the effect of this differential tail-off, others,
including Kirchoff et al [12], normalised the test peak
against the average of a small number of neighbouring
peaks (local normalisation). However, any abnormal
peak will skew the results of the peaks that use it for nor-
malisation. If this effect is substantial, then this can cause
a false-positive result.
The analysis method described in this paper, developed
and validated on a dataset of ~20,000 tested loci (208
cases, each tested two or three times), minimises any
manipulation of data (values are not pooled or averaged)
and considers each result independently of other results
from the same subtelomeric region. This method gener-
ates robust single probe results as shown by the data set
presented here. However, best practice still requires that
any result based on a single locus is confirmed by a sepa-
rate assay, either for the same locus, or for a nearby region.
We have chosen to follow up single probe results using
FISH, sequencing and/or realtime PCR, according to the
flow diagrams shown in Figures 4, 5 and 6. It is interesting
to note that in a separate case with a deletion profile, a sin-
gle base change 10 bp from the ligation site was identified
MLPA workflow for abnormal results in cases with two probe results Figure 4
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(data not shown). As the identification of any hetero-
zygous sequence change in the probe binding site pro-
vides evidence for the presence of two homologues, this
suggests that a single base change up to 10 bp away from
the ligation site can affect probe ligation and/or hybridi-
sation efficiency sufficiently to simulate a deletion.
Inheritance studies are required to determine if an abnor-
mality is de novo, which would suggest that it is associ-
ated with the abnormal phenotype. However, an
inherited abnormality is not necessarily unconnected to
the referral indication, and careful clinical assessment of
the carrier parent's phenotype is necessary to exclude sub-
tle abnormalities or unusual features. In addition, recent
studies [20-22] have shown that the incidence of "poly-
morphic" copy number variations (CNVs) in the genome
is higher than had previously been thought. Although
some of the MLPA probes in the subtelomeric assays have
been redesigned to account for CNVs, it is likely that
MLPA assays may continue to detect rare CNVs such as
cases 6 and 20 reported here. However, the possibility that
CNVs may be important in complex disease or suscepti-
bility traits cannot be excluded, and the collection and
collation of these findings will be an important contribu-
tion to our understanding of human variation. In addi-
tion, two samples (one from the validation study and
service case 15) both carry the same 3 bp change near the
ligation site of a MLPA probe for the 4q subtelomere
(P069). This is therefore likely to represent a population
polymorphism although further studies are required to
exclude expression of FRG1 being affected by this change
in the 5'-UTR sequence.
Overall, the 27 abnormal MLPA results found in the 455
patients tested as part of our clinical diagnostic service
(see Tables 3 and 4), represent an abnormality detection
rate of 5.9%, although some of these have yet to be con-
firmed, and some were inherited from apparently normal
MLPA workflow for abnormal results in cases with single probe duplications Figure 5
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parents, and may therefore be incidental findings. The
prevalence of "clinically significant" abnormalities may
therefore be as low as 1.3% and as high as 5.5%. Preva-
lence of subtelomere imbalance has previously been
reported as between 0 [1] and 10.7% [2], by FISH and pre-
vious MLPA studies. Detection rates in different studies
are likely to be influenced by two factors: first, the patient
group tested, and second, the resolution and quality of the
G-banded chromosome analysis carried out prior to
MLPA testing. Our tested group is now less phenotypically
defined than prior to MLPA, as we are able to test many
more samples, and no longer restricted to patients fulfill-
ing the de Vries criteria [19]. We would therefore expect
our detection rate to be lower than other groups still using
these criteria. In addition, our G-banded chromosome
analysis is routinely carried out at a minimum quality of
550 bands per haploid set, and usually at a higher quality.
This enables us to detect subtle abnormalities in the sub-
telomere regions and exclude these from MLPA testing. A
policy of "high resolution" chromosome analysis with
particular emphasis on the examination of telomeres has
previously been shown to reduce the detection rate by
FISH of subtelomere abnormalities [1].
Testing Strategy
The results of the validation study were used to develop a
testing strategy, which is now in use for our MLPA service
(see Figures 4, 5, 6). All samples are tested with 2 different
MLPA probes for each subtelomere and any abnormal
results are repeated to check for consistency. Naturally, if
the breakpoint for the abnormality occurs between the
two MLPA probes, only one probe will produce an abnor-
mal result. All abnormal MLPA results are routinely fol-
lowed-up with FISH analysis, which may confirm the
MLPA result, and/or provide positional information and
delineate breakpoints. However, as the relative positions
of commercial FISH and MLPA probes vary between
regions, FISH analysis may not be informative in some
cases. Developing further FISH probes could be one strat-
egy for aiding follow-up studies.
MLPA workflow for abnormal results in cases with single probe deletions Figure 6
MLPA workflow for abnormal results in cases with single probe deletions.BMC Medical Genetics 2007, 8:9 http://www.biomedcentral.com/1471-2350/8/9
Page 12 of 13
(page number not for citation purposes)
For samples where only one MLPA probe gives an abnor-
mal result, confirmation by another technique is consid-
ered necessary before reaching a conclusive diagnosis. As
mentioned above, FISH analysis is the first follow-up test.
When deletions identified by a single MLPA probe are not
confirmed by FISH (or FISH would be uninformative due
to relative probe positions), these cases are then followed
up by sequencing across the MLPA probe binding site (see
Figure 6). This identifies any sequence changes near the
ligation site, which can inhibit ligation of the MLPA probe
and simulate a deletion. If any heterozygous sequence
change is detected in the probe binding sequence, then,
regardless of the position of the sequence change, this
indicates the presence of two copies of this sequence. The
deletion detected by MLPA is therefore either due to this
sequence change or an artefact of the MLPA reaction. In
either case, it is unlikely to be clinically significant,
although a sequence change which may give rise to an
amino acid change in a critical region of a protein should
be considered. If no sequence change is detected, another
technique is still required to confirm the deletion. Quan-
titative realtime PCR is a promising approach for this role
and is currently in development at our Centre. Similarly,
duplications detected by a single MLPA probe require con-
firmation (see Figure 5) and again, realtime PCR assays
are being developed for this purpose for instances when
the FISH result is normal or would be uninformative.
Parental samples are requested for any patients with con-
firmed abnormal results to assess the clinical significance
of the findings. In addition, MLPA analysis of parental
samples may confirm single probe MLPA results if the
deletion (normal on sequence analysis) or duplication is
inherited.
Conclusion
MLPA is an extremely efficient, medium-thoughput tech-
nique; we routinely test 80 samples per week (including
patients from other referral groups not detailed here), and
on the grounds of both throughput and cost MLPA has
very considerable advantages over FISH. The detection of
imbalance across the genome by new methods such as
array-CGH will clearly increase the detection rate of
abnormalities in patients with developmental delay, dys-
morphism and mental retardation. However, array-CGH
is unlikely to be introduced into diagnostic service in a
state-funded health system for this substantial referral
group until the cost of the arrays is considerably less than
at present and/or cytogenetic services have been rational-
ised; until then, MLPA represents the best available
approach for detecting submicroscopic imbalance in
regions known to be gene-rich and prone to rearrange-
ments. The development of a straightforward and robust
analysis system for the interpretation of results from the
subtelomere assays will be of benefit to all Centres wish-
ing to implement this service.
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